Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derazantinib ADME Study in Healthy Males
NCT04098692Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of derazantinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Plasma Concentration at Day 50, Time to Maximum Plasma Concentration at Day 50 and 10 more. Started Aug 2019; status: completed.
02
Drugs
derazantinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04098692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098692.